CRISPR-Cas9 Knockout Screen Identifies Novel Treatment Targets in Childhood High-grade Glioma

Overview

Journal Clin Epigenetics

Publisher Biomed Central

Specialty Genetics

Date 2023 May 10

PMID 37161535

Authors

Anna Wenger

Ida Karlsson

Teresia Kling

Helena Caren

Affiliations

Soon will be listed here.

Abstract

Background: Brain tumours are the leading cause of cancer-related death in children, and there is no effective treatment. A growing body of evidence points to deregulated epigenetics as a tumour driver, particularly in paediatric cancers as they have relatively few genomic alterations, and key driver mutations have been identified in histone 3 (H3). Cancer stem cells (CSC) are implicated in tumour development, relapse and therapy resistance and thus particularly important to target. We therefore aimed to identify novel epigenetic treatment targets in CSC derived from H3-mutated high-grade glioma (HGG) through a CRISPR-Cas9 knockout screen.

Results: The knockout screen identified more than 100 novel genes essential for the growth of CSC derived from paediatric HGG with H3K27M mutation. We successfully validated 12 of the 13 selected hits by individual knockout in the same two CSC lines, and for the top six hits we included two additional CSC lines derived from H3 wild-type paediatric HGG. Knockout of these genes led to a significant decrease in CSC growth, and altered stem cell and differentiation markers.

Conclusions: The screen robustly identified essential genes known in the literature, but also many novel genes essential for CSC growth in paediatric HGG. Six of the novel genes (UBE2N, CHD4, LSM11, KANSL1, KANSL3 and EED) were validated individually thus demonstrating their importance for CSC growth in H3-mutated and wild-type HGG. These genes should be further studied and evaluated as novel treatment targets in paediatric HGG.

Citing Articles

Overexpression of proteasome 26S subunit non-ATPase 6 protein and its clinicopathological significance in intrahepatic cholangiocarcinoma.

Tang Z, Tang Y, Qin K, Li Q, Chen G, Huang Y World J Hepatol. 2024; 16(11):1282-1289.

PMID: 39606161 PMC: 11586755. DOI: 10.4254/wjh.v16.i11.1282.

Chromosomal instability: a key driver in glioma pathogenesis and progression.

Mazzoleni A, Awuah W, Sanker V, Bharadwaj H, Aderinto N, Tan J Eur J Med Res. 2024; 29(1):451.

PMID: 39227895 PMC: 11373396. DOI: 10.1186/s40001-024-02043-8.

References

Fejzo M, Chen H, Anderson L, McDermott M, Karlan B, Konecny G . Analysis in epithelial ovarian cancer identifies KANSL1 as a biomarker and target gene for immune response and HDAC inhibition. Gynecol Oncol. 2020; 160(2):539-546. DOI: 10.1016/j.ygyno.2020.11.008. View

Heshmati Y, Turkoz G, Harisankar A, Kharazi S, Bostrom J, Kamali Dolatabadi E . The chromatin-remodeling factor is required for maintenance of childhood acute myeloid leukemia. Haematologica. 2018; 103(7):1169-1181. PMC: 6029541. DOI: 10.3324/haematol.2017.183970. View

Conant D, Hsiau T, Rossi N, Oki J, Maures T, Waite K . Inference of CRISPR Edits from Sanger Trace Data. CRISPR J. 2022; 5(1):123-130. DOI: 10.1089/crispr.2021.0113. View

Hsu P, Scott D, Weinstein J, Ran F, Konermann S, Agarwala V . DNA targeting specificity of RNA-guided Cas9 nucleases. Nat Biotechnol. 2013; 31(9):827-32. PMC: 3969858. DOI: 10.1038/nbt.2647. View

Kumar S, Kim J . PLK-1 Targeted Inhibitors and Their Potential against Tumorigenesis. Biomed Res Int. 2015; 2015:705745. PMC: 4628734. DOI: 10.1155/2015/705745. View

Jones C, Baker S . Unique genetic and epigenetic mechanisms driving paediatric diffuse high-grade glioma. Nat Rev Cancer. 2014; 14(10). PMC: 4747023. DOI: 10.1038/nrc3811. View

Liang X, Potter J, Kumar S, Zou Y, Quintanilla R, Sridharan M . Rapid and highly efficient mammalian cell engineering via Cas9 protein transfection. J Biotechnol. 2015; 208:44-53. DOI: 10.1016/j.jbiotec.2015.04.024. View

Hart T, Chandrashekhar M, Aregger M, Steinhart Z, Brown K, MacLeod G . High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities. Cell. 2015; 163(6):1515-26. DOI: 10.1016/j.cell.2015.11.015. View

Cheng J, Fan Y, Xu X, Dou J, Tang Y, Zhong X . A small-molecule inhibitor of UBE2N induces neuroblastoma cell death via activation of p53 and JNK pathways. Cell Death Dis. 2014; 5:e1079. PMC: 3944268. DOI: 10.1038/cddis.2014.54. View

10.

Bao S, Wu Q, McLendon R, Hao Y, Shi Q, Hjelmeland A . Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006; 444(7120):756-60. DOI: 10.1038/nature05236. View

11.

Chan K, Fang D, Gan H, Hashizume R, Yu C, Schroeder M . The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression. Genes Dev. 2013; 27(9):985-90. PMC: 3656328. DOI: 10.1101/gad.217778.113. View

12.

Ostrom Q, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J . CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol. 2014; 16 Suppl 4:iv1-63. PMC: 4193675. DOI: 10.1093/neuonc/nou223. View

13.

Kling T, Wenger A, Caren H . DNA methylation-based age estimation in pediatric healthy tissues and brain tumors. Aging (Albany NY). 2020; 12(21):21037-21056. PMC: 7695434. DOI: 10.18632/aging.202145. View

14.

Silva-Evangelista C, Barret E, Menez V, Merlevede J, Kergrohen T, Saccasyn A . A kinome-wide shRNA screen uncovers vaccinia-related kinase 3 (VRK3) as an essential gene for diffuse intrinsic pontine glioma survival. Oncogene. 2019; 38(38):6479-6490. DOI: 10.1038/s41388-019-0884-5. View

15.

Chen J, Li Y, Yu T, McKay R, Burns D, Kernie S . A restricted cell population propagates glioblastoma growth after chemotherapy. Nature. 2012; 488(7412):522-6. PMC: 3427400. DOI: 10.1038/nature11287. View

16.

Bajpe P, Prahallad A, Horlings H, Nagtegaal I, Beijersbergen R, Bernards R . A chromatin modifier genetic screen identifies SIRT2 as a modulator of response to targeted therapies through the regulation of MEK kinase activity. Oncogene. 2014; 34(4):531-6. DOI: 10.1038/onc.2013.588. View

17.

Wu G, Diaz A, Paugh B, Rankin S, Ju B, Li Y . The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nat Genet. 2014; 46(5):444-450. PMC: 4056452. DOI: 10.1038/ng.2938. View

18.

Shalem O, Sanjana N, Hartenian E, Shi X, Scott D, Mikkelson T . Genome-scale CRISPR-Cas9 knockout screening in human cells. Science. 2013; 343(6166):84-87. PMC: 4089965. DOI: 10.1126/science.1247005. View

19.

Laugesen A, Hojfeldt J, Helin K . Role of the Polycomb Repressive Complex 2 (PRC2) in Transcriptional Regulation and Cancer. Cold Spring Harb Perspect Med. 2016; 6(9). PMC: 5008062. DOI: 10.1101/cshperspect.a026575. View

20.

Medvedeva Y, Lennartsson A, Ehsani R, Kulakovskiy I, Vorontsov I, Panahandeh P . EpiFactors: a comprehensive database of human epigenetic factors and complexes. Database (Oxford). 2015; 2015:bav067. PMC: 4494013. DOI: 10.1093/database/bav067. View